成都先导(688222) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 106,736,382.81, a decrease of 0.60% compared to CNY 107,382,466.51 in the same period last year[3] - Net profit attributable to shareholders increased by 102.90% to CNY 28,284,392.84 from CNY 13,940,028.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses rose by 113.63% to CNY 17,505,638.85, compared to CNY 8,194,191.46 in the previous year[3] - Basic earnings per share increased by 133.33% to CNY 0.07 from CNY 0.03 year-on-year[5] - Operating profit for Q1 2025 increased to CNY 31.19 million, up 115.5% from CNY 14.50 million in Q1 2024[17] - Net profit for Q1 2025 reached CNY 27.78 million, representing a 99.5% increase from CNY 13.91 million in Q1 2024[17] - The total comprehensive income attributable to the parent company's owners for Q1 2025 was CNY 31,802,078.64, compared to CNY 13,872,575.70 in Q1 2024, representing a significant increase[18] Cash Flow - The net cash flow from operating activities was CNY 67,703,013.64, reflecting a 65.67% increase from CNY 40,865,611.68 in the same period last year[3] - Cash inflow from operating activities totaled CNY 152,074,084.77 in Q1 2025, an increase from CNY 119,226,178.01 in Q1 2024, marking a rise of 27.55%[18] - Cash outflow from operating activities was CNY 84,371,071.13 in Q1 2025, compared to CNY 78,360,566.33 in Q1 2024, which is an increase of 7.66%[18] - The net cash flow from investing activities for Q1 2025 was -CNY 27,265,973.12, a decrease from CNY 56,428,214.18 in Q1 2024[19] - Cash inflow from investing activities in Q1 2025 was CNY 584,471,684.37, while cash outflow was CNY 27,265,973.12, indicating a net cash outflow[19] - Cash flow from financing activities generated a net inflow of CNY 2,309,134.87 in Q1 2025, compared to a net outflow of -CNY 3,035,925.21 in Q1 2024[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,809,160,583.98, a 3.00% increase from CNY 1,756,516,608.11 at the end of the previous year[5] - Total liabilities increased to CNY 355.39 million, up from CNY 334.04 million year-over-year[15] - The company reported cash and cash equivalents of ¥505,600,712.38 as of March 31, 2025, an increase from ¥462,184,981.34 at the end of December 2024[13] - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 505,237,993.26, up from CNY 467,109,403.98 in Q1 2024, showing an increase of 8.06%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,254[9] - The largest shareholder, JIN LI, holds 81,876,948 shares, representing 20.43% of total shares[10] - The second-largest shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., holds 46,770,579 shares, accounting for 11.67%[10] - There are no significant changes in the shareholder structure or relationships among the top shareholders[10] Research and Development - Research and development expenses totaled CNY 12,824,415.49, accounting for 12.02% of operating revenue, a slight decrease from 12.10% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 12.82 million, slightly down from CNY 12.99 million in Q1 2024[17] Other Income and Gains - The company reported a significant increase in other income to CNY 7.86 million, compared to CNY 1.57 million in the previous year[17] - Government subsidies increased year-on-year, contributing to the significant rise in net profit attributable to shareholders[7] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2025[20] Revenue Analysis - The company attributed the decline in operating revenue primarily to reduced milestone income from its UK subsidiary Vernalis (R&D) Limited, while excluding this, the group experienced an 8% year-on-year growth[7]